June 29, 2017 / 11:15 AM / 2 months ago

BRIEF-Proteostasis Therapeutics reports preliminary data from phase 1 study of pti-428

June 29 (Reuters) - Proteostasis Therapeutics Inc:

* Proteostasis Therapeutics reports preliminary data from phase 1 study of pti-428 in patients with cystic fibrosis

* Proteostasis Therapeutics - pti-428 generally well tolerated, no serious adverse events, no adverse events leading to discontinuation observed

* Proteostasis Therapeutics-separate study with third patient population is initiating enrollment of cf patients who will receive pti-428 in addition to kalydeco Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below